Who
Nicholas Donoghoe
EVP, Chief Bus/Strat Officer
Company insider
Files Form 4 as: EVP, Chief Bus/Strat Officer, AbbVie.
In numbers
- Trades disclosed
- 41
- Buys
- 1
- Sells
- 4
- Bought
- $498K
- Sold
- $23.2M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 2 Jan 2019
- Last trade
- 14 Aug 2026
- Last filed
- 18 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Aug 2026filed 18 Aug 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code M | $2.6M32,710 at $79.02 | filing |
| 14 Aug 2026filed 18 Aug 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Sold | $8.2M32,710 at $250.00 | filing |
| 14 Aug 2026filed 18 Aug 2026 | ABBV AbbVieoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —32,710 at $0.00 | filing |
| 14 Aug 2026filed 18 Aug 2026 | ABBV AbbVieoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —32,710 at $0.00 | filing |
| 14 Aug 2026filed 18 Aug 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code M | $2.6M32,710 at $79.02 | filing |
| 14 Aug 2026filed 18 Aug 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Sold | $8.2M32,710 at $250.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code F | $3.0M12,874 at $232.08 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code F | $3.0M12,874 at $232.08 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code A | —13,031 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code A | —4,632 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code A | —5,172 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ABBV AbbVieoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,312 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code A | —6,222 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ABBV AbbVieoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,312 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code A | —13,031 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code A | —4,632 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code A | —5,172 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code A | —6,222 at $0.00 | filing |
| 5 Aug 2025filed 7 Aug 2025 | ABBV AbbViePharmaceuticals | SEC FORM 4 Sold | $641K3,234.17 at $198.27 | filing |
| 5 Aug 2025filed 7 Aug 2025 | ABBV AbbViePharmaceuticals | SEC FORM 4 Sold | $2.0M10,061 at $198.59 | filing |
News
U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's DiseaseABBV · prnewswire.com · 23 Oct 2026AbbVie (NYSE:ABBV) & TScan Therapeutics (NASDAQ:TCRX) Financial ComparisonABBV · tickerreport.com · 22 Oct 2026AbbVie reaches agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for ELAHERE® in Platinum-Resistant Ovarian CancerABBV · cantechletter.com · 21 Oct 2026
0 headlines in the last 90 days name Nicholas Donoghoe; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.